Contineum CSO sells shares, exercises options
Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain reported mixed equity transactions in Class A Common Stock.
Rhea-AI Filing Summary
Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain reported mixed equity transactions in Class A Common Stock. On June 30 and July 1, he sold a total of 37,179 shares in open-market trades at weighted average prices around $15.67–$16.24 per share under a pre-arranged Rule 10b5-1 trading plan. He also exercised stock options for 33,009 shares at an exercise price of $1.01 per share, converting options into common stock. After these transactions, he holds 135,202 shares directly and 10,110 shares indirectly through his spouse, along with 34,297 fully vested stock options that remain exercisable.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
8 txns
Insider
Lorrain Daniel S.
Role
Chief Scientific Officer
Sold
37,179 shs ($595K)
Approx. gross sale proceeds
$595K
Approx. exercise cost
$33K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 4,183 | $0.00 | $0.00 |
| Exercise | Class A Common Stock | 4,183 | $1.01 | $4K |
| Sale | Class A Common Stock | 5,852 | $15.6667 | $92K |
| Sale | Class A Common Stock | 2,501 | $16.2369 | $41K |
| Exercise | Stock Option (right to buy) | 28,826 | $0.00 | $0.00 |
| Exercise | Class A Common Stock | 28,826 | $1.01 | $29K |
| Sale | Class A Common Stock | 28,826 | $16.0372 | $462K |
| holding | Class A Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 34,297 contracts (Direct);
Class A Common Stock — 135,202 shares (Direct);
Class A Common Stock — 10,110 shares (Indirect, By Spouse)
Footnotes (6)
- F1. These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.35, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.15 to $16.14, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.16 to $16.40, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- F5. Includes 6,537 shares of the Issuer's Class A Common Stock acquired by the Reporting Person's spouse in one or more transactions with the Issuer pursuant to its Employee Stock Purchase Plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c).
- F6. The stock options are fully vested and exercisable.
Key Figures
Shares sold: 37,179 shares
Sale prices: $15.15–$16.40/share
Options exercised: 33,009 shares
+5 more
8 metrics
Shares sold
37,179 shares
Net open-market sales of Class A Common Stock over June 30–July 1, 2026
Sale prices
$15.15–$16.40/share
Weighted average sale price ranges from multiple transactions
Options exercised
33,009 shares
Total Class A Common shares acquired via option exercises
Exercise price
$1.01/share
Conversion or exercise price for exercised stock options
Direct holdings after trades
135,202 shares
Direct Class A Common Stock ownership following reported transactions
Indirect holdings
10,110 shares
Class A Common Stock held indirectly by spouse as reported
Remaining stock options
34,297 options
Fully vested stock options remaining outstanding after exercises
10b5-1 plan adoption date
September 23, 2025
Date CSO adopted the Rule 10b5-1 trading plan governing these trades
Key Terms
Rule 10b5-1 trading plan, weighted average price, Employee Stock Purchase Plan, Stock Option (right to buy), +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging..."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Employee Stock Purchase Plan financial
"Includes 6,537 shares of the Issuer's Class A Common Stock acquired by the Reporting Person's spouse... pursuant to its Employee Stock Purchase Plan..."
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
Stock Option (right to buy) financial
"Stock Option (right to buy) with underlying security title Class A Common Stock"
fully vested and exercisable financial
"The stock options are fully vested and exercisable."
FAQ
What insider transactions did Contineum Therapeutics (CTNM) report for Daniel S. Lorrain?
Contineum Therapeutics reported that Chief Scientific Officer Daniel S. Lorrain sold 37,179 Class A Common shares and exercised options for 33,009 shares. The activity combined open-market sales with option exercises over June 30 and July 1, 2026, under a pre-arranged trading plan.
What stock options did the Contineum Therapeutics (CTNM) CSO exercise?
He exercised stock options for 33,009 shares of Class A Common Stock at a conversion or exercise price of $1.01 per share. These included 28,826 shares on June 30 and 4,183 shares on July 1, 2026, from fully vested and exercisable option grants.
Were the Contineum Therapeutics (CTNM) insider sales made under a Rule 10b5-1 plan?
Yes. The Form 4 states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 23, 2025. Such plans schedule trades in advance, making the timing more routine rather than discretionary.
Does the Contineum Therapeutics (CTNM) filing show any indirect holdings by the CSO’s spouse?
Yes. The filing reports 10,110 shares of Class A Common Stock as indirectly owned “By Spouse.” Footnotes explain this includes 6,537 shares acquired through the issuer’s Employee Stock Purchase Plan in exempt transactions under specified SEC rules.
AI-generated analysis. How Rhea-AI works. Not financial advice.
